tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Psyence Biomedical Trials Psilocybin for Palliative Care

Story Highlights
Psyence Biomedical Trials Psilocybin for Palliative Care

Psyence Group (TSE:PSYG) has released an update.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Psyence Group’s associate, Psyence Biomedical, has initiated a clinical trial in Australia to study the effects of nature-derived psilocybin on Adjustment Disorder in palliative care. The Phase IIb study will be supported by partnerships with Fluence and iNGENū CRO Pty Ltd, and marks progress in exploring psilocybin’s potential for treating mental health conditions.

For further insights into TSE:PSYG stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1